Company profile: USGI Medical
1.1 - Company Overview
Company description
- Provider of incisionless surgical technologies for gastrointestinal procedures, offering the Incisionless Operating Platform to address GI procedural challenges; the POSE2.0 endoscopic gastroplasty using Snowshoe Suture Anchors to provide gastric restriction without removing part of the stomach; and tools including the g-Cath Tissue Anchor Delivery Catheter, g-Prox EZ Endoscopic Grasper, and Transport Endoscopic Guide.
Products and services
- POSE2.0: An endoscopic gastroplasty procedure that uses the Incisionless Operating Platform to place Snowshoe Suture Anchors in gastric tissue, producing gastric restriction without removing part of the stomach
- Incisionless Operating Platform (IOP): An incisionless platform consisting of four devices that address procedural challenges within the gastrointestinal tract, enabling surgeries through natural passageways without external incisions
- Snowshoe Suture Anchors: Proprietary anchors that create durable, permanent tissue folds within the gastrointestinal tract, placed in gastric tissue using the Incisionless Operating Platform during POSE2.0
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to USGI Medical
NGM Bio
HQ: United States
Website
- Description: Provider of biotherapeutic drug discovery focused on the gastrointestinal endocrine system, developing: NGM707 (ILT2/ILT4 antagonist), NGM831 (ILT3 antagonist), NGM438 (LAIR1 antagonist) for advanced solid tumors; NGM120 (GFRAL antagonist) for advanced solid tumors and cachexia; NGM621 (anti-Complement C3) for geographic atrophy; aldafermin (FGF19 analog) for NASH F4 and primary sclerosing cholangitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NGM Bio company profile →
Akarna Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development of novel small molecule therapeutics targeting inflammatory and fibrotic diseases, including a non-bile acid FXR agonist for nonalcoholic steatohepatitis (NASH), aiming to deliver best-in-class treatments for chronic liver diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akarna Therapeutics company profile →
Enobia Pharma
HQ: Canada
Website
- Description: Provider of therapies for serious genetic bone disorders, focused on conditions with no approved treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enobia Pharma company profile →
Sigilon Therapeutics
HQ: United States
Website
- Description: Provider of immune-privileged, immune-protected engineered human cell products to treat acute and chronic diseases by restoring normal physiology while aiming to avoid fibrosis and immune rejection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sigilon Therapeutics company profile →
Nexus BioPharma
HQ: United States
Website
- Description: Provider of preclinical-stage biotechnology research and development focused on developing new therapies and intellectual property.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nexus BioPharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for USGI Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to USGI Medical
2.2 - Growth funds investing in similar companies to USGI Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for USGI Medical
4.2 - Public trading comparable groups for USGI Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →